[1] Felson DT,Zhang Y, Anthony JM, et al.Weight loss reduces the risk for symptomatic knee osteoarthritis in women: The Framingham Study. Ann Intern Med.1992;116:535-539.
[2] Pottie P, Presle N, Terlain B, et al. Obesity and osteoarthritis: more complex than predicted. Ann Rheum Dis.2006; 65: 1403-1405.
[3] Conde J, Scotece M,Gomez R,et al. Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis.2011; 2011:203901.
[4] Lehrke M,Becker A,Greif M,et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol.2009;161:339-344.
[5] Weigert J,Neumeier M,Wanninger J,et al.Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol.2010;72:342-348.
[6] Eisinger K, Bauer S, Schäffler A, et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis.Experimental and Molecular Pathology.2012;92:90-96.
[7] Berg V, Sveinbjornsson B, Bendiksen S, et al. Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157), Arthritis Research and Therapy. 2010;12:228.
[8] Christensen R, Astrup A, Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage. 2005;13(1):20-27.
[9] Conde J, Scotece M, GomezR,et al. Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis.2011;2011:203901.
[10] Koskinen A, Vuolteenaho K, Nieminen R, et al. Leptin enhances MMP-1,MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol. 2011; 29:57-64.
[11] Hao D, Li M, Wu Z, et al. Synovial fluid level of adiponectin correlated with levels of aggrecan degradation makers in osteoarthritis. Rheumatol Int.2011;31:1433-1437.
[12] Koskinen A, Juslin S, Nieminen R, et al. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. Arthritis Res Ther.2011;13:R184.
[13] Duan Y, Hao D, Li M, et al. Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int. 2012;32:985-990.
[14] Klein-Wieringa IR, Kloppenburg M, Bastiaa nsen-Jenni-skens YM, et al. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann Rheum Dis.2011;70:851-857.
[15] 王晓娟,颜建英.脂肪细胞因子chemerin的研究进展[J].国际妇产科杂志,2010;37:43-46.
[16] Wittamer V, Bondue B, Guillabert A, et al. Neutrophil- mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol.2005;175:487-493.
[17] Landgraf K, Friebe D, Ullrich T, et al. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab.2012;97:e556-564.
[18] Pfau D, Bachmann A, Lossner U, et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care.2010;33:171-173.
[19] Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol.2010;72:342-348.
[20] Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Matab.2010;95:2892-2896.
[21] Conde J, Gomez R, Bianco G, et al. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes, Annals of the Rheumatic Diseases.2011;70:551-559.
[22] Lehrke M, Becker A, Greif M, et al.Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol.2009;161:339-344.
[23] Hart R,Greaves DR.Chemerin contributes to inflammation by promoting macrophage adhesion to VACM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010; 185:3728-3739.
[24] Eisinger K, Bauer S, Schaffler A, et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis.Exp Mol Pathol. 2012; 92(1):90-96.
[25] Huang K, Du G,Li L, et al. Association of chemerin levels in synovial fluid with the severity of knee osteoarthritis. Biomarkers.2012,17(1):16-20.
[26] Hu PF, Tang JL, Chen WP, et al. Increased apelin serum levels and expression in human chondrocytes in osteoarthritic patients. Int Orthop.2011;35:1421-1426.
[27] Scotece M, Conde J, GOmez R, et al. Beyond fat mass: exploring the role of adipokine in rheumatic diseases. Sci World J.2011;11:1932-1947.
[28] Choi HM, Lee YA, Lee SH, et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase- 13 expression in fibroblastlike synoviocytes more than proinflammatory mediation. Arthritis Res Ther.2009;11: R161.
[29] Gosset M, Berenbaum F,Salvat C, et al. Crucial role of visfatin/pre-β cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: Possible influence on osteoarthritis. Arthritis and Rheumatism.2008;58:1399-1409.
[30] Berry PA, Jones SW, Cicuttini FM, et al. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum. 2011;63:700-707. |